^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SCO-120

    i
    Other names: SCO-120
    Associations

    News

    Trials
    Company:
    Sun Pharma Advanced Research Company
    Drug class:
    Selective estrogen receptor α degrader
    Related drugs:
    Associations

    News

    Trials
    12ms
    A Study in Patients With Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=9, Terminated, Sun Pharma Advanced Research Company Limited | N=167 --> 9 | Trial completion date: Jan 2024 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Jan 2024 --> Feb 2023; The decision to close is due commercial reasons only
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive • HER-2 negative • ER mutation • ESR1 mutation
    |
    SCO-120
    almost2years
    A Study in Patients With Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=141, Recruiting, Sun Pharma Advanced Research Company Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive • HER-2 negative • ER mutation • ESR1 mutation
    |
    SCO-120
    over2years
    A Study in Patients With Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=141, Not yet recruiting, Sun Pharma Advanced Research Company Limited | Initiation date: Jan 2022 --> Apr 2022
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive • HER-2 negative • ER mutation • ESR1 mutation
    |
    SCO-120
    over2years
    A Study in Patients With Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=141, Not yet recruiting, Sun Pharma Advanced Research Company Limited | Initiation date: Oct 2021 --> Jan 2022
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive • HER-2 negative • ER mutation • ESR1 mutation
    |
    SCO-120
    almost3years
    A Study in Patients With Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=141, Not yet recruiting, Sun Pharma Advanced Research Company Limited
    Clinical • New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 negative • HER-2 mutation • ER mutation
    |
    SCO-120